Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting

Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30–50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthroug...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomed Res Int
Hlavní autor: Navari, Rudolph M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2015
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4573228/
https://ncbi.nlm.nih.gov/pubmed/26421294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/595894
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky